Patient characteristics
| . | Idecabtagene vicleucel (n = 42) . | Ciltacabtagene autoleucel (n = 38) . | Overall (N = 80) . |
|---|---|---|---|
| Age, y | |||
| Mean (SD) | 65.8 (7.95) | 64.7 (7.92) | 65.3 (7.90) |
| Median (min, max) | 66.0 (41.0, 80.0) | 65.0 (43.0, 80.0) | 66.0 (41.0, 80.0) |
| Sex | |||
| Male | 24 (57.1%) | 25 (65.8%) | 49 (61.3%) |
| Female | 18 (42.9%) | 13 (34.2%) | 31 (38.8%) |
| CRS | |||
| CRS 1 | 27 (64.3%) | 15 (39.5%) | 42 (52.5%) |
| CRS 2 | 8 (19.0%) | 17 (44.7%) | 25 (31.3%) |
| CRS 3 | 5 (11.9%) | 0 (0%) | 5 (6.3%) |
| None | 2 (4.8%) | 6 (15.8%) | 8 (10.0%) |
| ICANS | |||
| ICANS 1 | 7 (16.7%) | 3 (7.9%) | 10 (12.5%) |
| ICANS 2 | 0 (0%) | 1 (2.6%) | 1 (1.3%) |
| None | 35 (83.3%) | 34 (89.5%) | 69 (86.3%) |
| Tocilizumab | |||
| Yes | 38 (90.5%) | 31 (81.6%) | 69 (86.3%) |
| Dexamethasone | |||
| Yes | 20 (25.0%) | 21 (26.3%) | 41 (51.3%) |
| No. of prior therapies | |||
| Mean (SD) | 7.14 (2.65) | 6.37 (2.99) | 6.78 (2.82) |
| Median (min, max) | 7.00 (2.00, 14.0) | 6.00 (2.00, 14.0) | 6.50 (2.00, 14.0) |
| Infection 30 d before CAR T cells | |||
| Yes | 14 (33.3%) | 4 (10.5%) | 18 (22.5%) |
| No | 28 (66.7%) | 34 (89.5%) | 62 (77.5%) |
| Antimicrobial prophylaxis | |||
| Double (valacyclovir/cotrimoxazole) | 37 (88.1%) | 29 (76.3%) | 66 (82.5%) |
| Single (valacyclovir) | 0 (0%) | 6 (15.8%) | 6 (7.5%) |
| Any infection after CAR T cells | |||
| Yes | 28 (66.7%) | 29 (76.3%) | 57 (71.3%) |
| . | Idecabtagene vicleucel (n = 42) . | Ciltacabtagene autoleucel (n = 38) . | Overall (N = 80) . |
|---|---|---|---|
| Age, y | |||
| Mean (SD) | 65.8 (7.95) | 64.7 (7.92) | 65.3 (7.90) |
| Median (min, max) | 66.0 (41.0, 80.0) | 65.0 (43.0, 80.0) | 66.0 (41.0, 80.0) |
| Sex | |||
| Male | 24 (57.1%) | 25 (65.8%) | 49 (61.3%) |
| Female | 18 (42.9%) | 13 (34.2%) | 31 (38.8%) |
| CRS | |||
| CRS 1 | 27 (64.3%) | 15 (39.5%) | 42 (52.5%) |
| CRS 2 | 8 (19.0%) | 17 (44.7%) | 25 (31.3%) |
| CRS 3 | 5 (11.9%) | 0 (0%) | 5 (6.3%) |
| None | 2 (4.8%) | 6 (15.8%) | 8 (10.0%) |
| ICANS | |||
| ICANS 1 | 7 (16.7%) | 3 (7.9%) | 10 (12.5%) |
| ICANS 2 | 0 (0%) | 1 (2.6%) | 1 (1.3%) |
| None | 35 (83.3%) | 34 (89.5%) | 69 (86.3%) |
| Tocilizumab | |||
| Yes | 38 (90.5%) | 31 (81.6%) | 69 (86.3%) |
| Dexamethasone | |||
| Yes | 20 (25.0%) | 21 (26.3%) | 41 (51.3%) |
| No. of prior therapies | |||
| Mean (SD) | 7.14 (2.65) | 6.37 (2.99) | 6.78 (2.82) |
| Median (min, max) | 7.00 (2.00, 14.0) | 6.00 (2.00, 14.0) | 6.50 (2.00, 14.0) |
| Infection 30 d before CAR T cells | |||
| Yes | 14 (33.3%) | 4 (10.5%) | 18 (22.5%) |
| No | 28 (66.7%) | 34 (89.5%) | 62 (77.5%) |
| Antimicrobial prophylaxis | |||
| Double (valacyclovir/cotrimoxazole) | 37 (88.1%) | 29 (76.3%) | 66 (82.5%) |
| Single (valacyclovir) | 0 (0%) | 6 (15.8%) | 6 (7.5%) |
| Any infection after CAR T cells | |||
| Yes | 28 (66.7%) | 29 (76.3%) | 57 (71.3%) |
Max, maximum; min, minimum; SD, standard deviation.